CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard of care treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug304 Favipiravir Wiki 0.41

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.12
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19

The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

NCT04346628 COVID Drug: Favipiravir Other: Standard of care treatment

Primary Outcomes

Description: Time in days from randomization to a negative result of nasopharyngeal and/or oropharyngeal and/or salivary swab.

Measure: Time until cessation of oral shedding of SARS-CoV-2 virus

Time: Up to 28 days

Secondary Outcomes

Description: Clinical worsening will be determined by clinician assessment.

Measure: Count of participants with clinical worsening of COVID-19 disease

Time: Up to 28 days

Description: Viral load will be assessed as the TCID50 (Median Tissue Culture Infectious Dose) over time.

Measure: Sars-CoV-2 viral load

Time: Up to 28 days

Measure: Count of participants with development of SARS-CoV-2 antibodies

Time: Up to 28 days

Measure: Time until cessation of symptoms

Time: Up to 28 days

Description: Cmax is a pharmacokinetic parameter that measures the maximum concentration of drug in plasma.

Measure: Cmax of favipiravir

Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)

Description: Cmin is a pharmacokinetic parameter that measures the minimum concentration of drug in plasma.

Measure: Cmin of favipiravir

Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)


No related HPO nodes (Using clinical trials)